Beta blockers still relevant

Jaroslav Brotánek

Cor Vasa 2021, 63(2):272-275 | DOI: 10.33678/cor.2021.032  

Current clinical practice continues to regard beta blockers as very important drugs in a number of indica-tions. What should be taken into account, however, is that individual beta blockers vary and that the diffe-rences between them may infl uence the overall treatment effect or side effects. In choosing the appropriate beta blockers, we should focus on the beta-1 selective agents which have good pharmacokinetic properties and whose effi cacy has been proved by a whole range of clinical trials.

2020 ESC Guidelines for the diagnosis and management of atrial fi brillation. Summary of the document prepared by the Czech Society of Cardiology

Martin Fiala, Luděk Haman, Robert Čihák

Cor Vasa 2021, 63(2):135-161 | DOI: 10.33678/cor.2021.038  

© 2021 European Society of Cardiology. All rights reserved. Published by the Czech Society of Cardiology.

(2020 ESC Guidelines for the management of adult congenital heart disease. Summary of the document prepared by the Czech Society of Cardiology)

Dan Marek, Roman A. Gebauer, Martin Mates, Jana Rubáčková Popelová, Petra Antonová, Tomáš Zatočil

Cor Vasa 2021, 63(2):163-195 | DOI: 10.33678/cor.2021.054  

© 2021 European Society of Cardiology. All rights reserved. Published by the Czech Society of Cardiology.

(2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Summary of the document prepared by
the Czech Society of Cardiology)

Zuzana Moťovská, Petr Kala, Martin Hutyra, Milan Hromádka

Cor Vasa 2021, 63(2):197-234 | DOI: 10.33678/cor.2021.039  

© 2021 European Society of Cardiology. All rights reserved. Published by the Czech Society of Cardiology.

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.  Summary of the document prepared by the Czech Society of Cardiology

Vladimír Tuka, Otakar Jiravský, Peter Kubuš, Eliška Sovová

Cor Vasa 2021, 63(2):235-262 | DOI: 10.33678/cor.2021.009  

© 2021 European Society of Cardiology. All rights reserved. Published by the Czech Society of Cardiology.

2021 ACC update of the heart failure guidelines

Jindřich Špinar, Filip Málek, Lenka Špinarová, Jiří Vítovec, Miloš Táborský, Aleš Linhart

Cor Vasa 2021, 63(2):264-270 | DOI: 10.33678/cor.2021.033  

The American College of Cardiology has published an update of the heart failure guidelines treatment in the beginning of the year 2021. We bring short information about this document. It is expected that the European Society of Cardiology will publish new European guidelines this year, which will probably confi rm the increasing indication for sacubitril valsartan (ARNI) and for SGLT2 inhibitors, as a new drug class for heart failure treatment. The percutaneous access for the treatment of mitral regurgitation is also a new one. The whole document has 32 pages.

Dětská kardioložka MUDr. Marie Voříšková 90letá

Jan Janoušek

Cor Vasa 2021, 63(2):279-280  

MUDr. Karel Roztočil, CSc., osmdesátníkem

Doc. MUDr. Debora Karetová, CSc.

Cor Vasa 2021, 63(2):281-282  

HOT lines na sjezdu ČKS 2021

Prof. MUDr. Jindřich Špinar, CSc.

Cor Vasa 2021, 63(2):284-286  

František Várnay a kol: Spiroergometrie v kardiologii a sportovní medicíně

Doc. MUDr. Vladimír Tuka, Ph.D.,

Cor Vasa 2021, 63(2):287  

Ondřej Fabián, David Kachlík: Patologická anatomie vývojových vad srdce

MUDr. Ondřej Fabián

Cor Vasa 2021, 63(2):288